Google+ Facebook Twitter Twitter

New vaccine boosts hopes of eliminating meningococcal meningitis

A trial of a new vaccine against meningococcal disease, a cause of meningitis and blood poisoning, has found that it is safe and induces a strong immune response across five serogroups of meningococcal bacteria: A, C, W, Y and X.

The phase 3 trial compared the immune response generated by the new pentavalent vaccine NmCV-5 against that of the licensed quadrivalent MenACWY-D vaccine in 1800 healthy 2–29-year-olds in Mali and The Gambia.

After 28 days, across all ages, the immune responses generated by a single dose of NmCV-5 were generally higher than those generated by MenACWY-D.

In addition, NmCV-5 induced a strong immune response to the emerging meningococcal X serogroup for which there is currently no licensed vaccine.

The trial found no safety concerns with NmCV-5.

Image Credit | iStock


Related Articles

New vaccine against malaria

The World Health Organization (WHO) has recommended a new vaccine, R21/Matrix-M, for the prevention of malaria in children.

Why didn’t people in the US get COVID-19 boosters?

More than 80% of the people in the US who were eligible to receive a COVID-19 booster last autumn did not have the jab.

Suppressing autoimmunity

Researchers have uncovered new details about how the immune system prevents the production of antibodies that can recognise and damage healthy tissues.

Unparalleled depth of data

Professor of Respiratory Research Louise Wain discusses an ongoing research project into the medium- and long-term effects of COVID.